| In vivo effects of a GPR30 antagonist MK Dennis, R Burai, C Ramesh, WK Petrie, SN Alcon, TK Nayak, ... Nature chemical biology 5 (6), 421-427, 2009 | 617 | 2009 |
| Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and … C Klein, I Waldhauer, VG Nicolini, A Freimoser-Grundschober, T Nayak, ... Oncoimmunology 6 (3), e1277306, 2017 | 250 | 2017 |
| Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges TK Nayak, MW Brechbiel Bioconjugate chemistry 20 (5), 825-841, 2009 | 245 | 2009 |
| 213Bi-[DOTA0, Tyr3] octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model JP Norenberg, BJ Krenning, IRHM Konings, DF Kusewitt, TK Nayak, ... Clinical Cancer Research 12 (3), 897-903, 2006 | 131 | 2006 |
| Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model CV Pastuskovas, EE Mundo, SP Williams, TK Nayak, J Ho, S Ulufatu, ... Molecular cancer therapeutics 11 (3), 752-762, 2012 | 124 | 2012 |
| Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti–fibroblast activation protein antibody correlates with severity of arthritis P Laverman, T van der Geest, SYA Terry, D Gerrits, B Walgreen, ... Journal of Nuclear Medicine 56 (5), 778-783, 2015 | 114 | 2015 |
| First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors CW Menke-van der Houven, C Gomez-Roca, C van Herpen, AL Coveler, ... Oncotarget 7 (48), 80046, 2016 | 97 | 2016 |
| PET imaging of tumor angiogenesis in mice with VEGF‐A–targeted 86Y‐CHX‐A ″‐DTPA‐bevacizumab TK Nayak, K Garmestani, KE Baidoo, DE Milenic, MW Brechbiel International journal of cancer 128 (4), 920-926, 2011 | 96 | 2011 |
| Somatostatin-receptor-targeted α-emitting 213Bi is therapeutically more effective than β−-emitting 177Lu in human pancreatic adenocarcinoma cells TK Nayak, JP Norenberg, TL Anderson, ER Prossnitz, MG Stabin, ... Nuclear medicine and biology 34 (2), 185-193, 2007 | 96 | 2007 |
| PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1–targeted 89Zr-labeled Panitumumab TK Nayak, K Garmestani, DE Milenic, MW Brechbiel Journal of Nuclear Medicine 53 (1), 113-120, 2012 | 93 | 2012 |
| PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab TK Nayak, CAS Regino, KJ Wong, DE Milenic, K Garmestani, KE Baidoo, ... European journal of nuclear medicine and molecular imaging 37, 1368-1376, 2010 | 93 | 2010 |
| First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2/anti-VEGF-A antibody, in adult patients with advanced solid tumors M Hidalgo, M Martinez-Garcia, C Le Tourneau, C Massard, E Garralda, ... Clinical Cancer Research 24 (7), 1536-1545, 2018 | 90 | 2018 |
| Implementing liquid biopsies into clinical decision making for cancer immunotherapy D Quandt, HD Zucht, A Amann, A Wulf-Goldenberg, C Borrebaeck, ... Oncotarget 8 (29), 48507, 2017 | 86 | 2017 |
| Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma TK Nayak, K Garmestani, KE Baidoo, DE Milenic, MW Brechbiel Journal of Nuclear Medicine 51 (6), 942-950, 2010 | 82 | 2010 |
| Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy I Waldhauer, V Gonzalez-Nicolini, A Freimoser-Grundschober, TK Nayak, ... MAbs 13 (1), 1913791, 2021 | 74 | 2021 |
| 86Y based PET radiopharmaceuticals: radiochemistry and biological applications T K Nayak, M W Brechbiel Medicinal Chemistry 7 (5), 380-388, 2011 | 72 | 2011 |
| Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy B Ribba, C Boetsch, T Nayak, HP Grimm, J Charo, S Evers, C Klein, ... Clinical Cancer Research 24 (14), 3325-3333, 2018 | 70 | 2018 |
| Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials DE Milenic, KJ Wong, KE Baidoo, TK Nayak, CAS Regino, K Garmestani, ... MAbs 2 (5), 550-564, 2010 | 66 | 2010 |
| In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers KJ Wong, KE Baidoo, TK Nayak, K Garmestani, MW Brechbiel, DE Milenic EJNMMI research 1, 1-15, 2011 | 65 | 2011 |
| HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma … TK Nayak, K Garmestani, DE Milenic, KE Baidoo, MW Brechbiel PloS one 6 (3), e18198, 2011 | 65 | 2011 |
